Last updated on October 2017

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC to Characterize Risk of Herpetic Infection


Brief description of study

A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients

Clinical Study Identifier: NCT02910557

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Amgen Call Center

Research Site
Knoxville, TN United States
  Connect »

Amgen Call Center

Research Site
Linz, Austria
  Connect »

Amgen Call Center

Research Site
Salzburg, Austria
  Connect »

Amgen Call Center

Research Site
Sankt Poelten, Austria
  Connect »